NDATRANSDERMALFILM, EXTENDED RELEASE
Approved
Aug 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
5/8 — Partial
COMBIPATCH (estradiol/norethindrone acetate transdermal system) by Noven Pharmaceuticals is estrogen receptor agonists [moa]. Approved for a woman with a uterus for: treatment of moderate to severe vasomotor symptoms due to menopause. First approved in 1998.
Drug data last refreshed 13h ago · AI intelligence enriched 16h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
COMBIPATCH is a transdermal estradiol/norethindrone acetate combination patch approved for moderate to severe vasomotor symptoms (hot flashes) in menopausal women with an intact uterus. It delivers estrogen via skin absorption using an extended-release film technology. The estrogen agonist mechanism alleviates menopausal vasomotor symptoms while norethindrone acetate provides endometrial protection.
$5MPart D
LOE ApproachingLate-stage product with modest Part D spending signals a mature, niche franchise requiring operational excellence and cost management rather than growth-focused expansion.
Mechanism of Action
Estrogen Receptor Agonists
Pharmacologic Class:
Estrogen
Career Relevance
COMBIPATCH career opportunities are concentrated in manufacturing and quality functions, reflecting a mature, stable product requiring operational excellence and regulatory compliance. Working on this product offers hands-on manufacturing and QA expertise in transdermal delivery systems but limited commercial strategy or medical affairs advancement.
Worked on COMBIPATCH at Noven Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.